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Abstract—Exhaled breath contains more than 1000 con-
stituents at trace level concentrations, with a wide variety of
these compounds potentially serving as biomarkers for specific
diseases, physiologic status, or therapeutic progress. Some of the
compounds in exhaled breath (EB) are well studied, and their
relationship with disease pathologies is well established. However,
molecularly specific analysis of such biomarkers in EB at clinically
relevant levels remains an analytical and practical challenge due
to the low levels of such biomarkers frequently below the ppb (v/v)
range in EB. In this contribution, mid-infrared (MIR) spectro-
scopic sensing techniques are reviewed for potential application in
breath diagnostics. While the spectral regime from 3–20   has
already been utilized for fundamental studies on breath analysis,
significant further improvements are in demand for substantiating
MIR spectroscopy and sensing techniques as a suitable candidate
for clinically deployable breath analyzers. Several advantageous
features including inherent molecular selectivity, real-time mon-
itoring capability, comparable ease of operation, potentially low
costs, and a compact device footprint promise reliable optical
diagnostics in the MIR. Hence, while the application of MIR
spectroscopy and sensing systems to breath analysis yet appear
in their infancy, recent progress on advanced MIR light sources,
waveguides, and device concepts forecasts next-generation optical
sensing platforms suitable for addressing the challenges of in situ
breath diagnostics.
Index Terms—Absorption spectroscopy, breast cancer, chem-
ical sensor, exhaled breath (EB), exhaled breath condensate
(EBC), exposure monitoring, hollow waveguide, infrared sensor,
mid-infrared (MIR), optical sensor, planar waveguide, quantum
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I. INTRODUCTION
I T is well established that exhaled breath (EB) from pa-tients suffering specific diseases contains distinctive scents,
as documented for a long time in both eastern and western cul-
ture. The analysis of breath is among the oldest diagnostic tech-
niques in medical practice characterizing diseases by specific
odors [1]. For ages it was believed that expired breath from pa-
tients may contain chemicals related to specific diseases without
validation of this hypothesis. In 1971, Linus Pauling pioneered
the analytical assessment of breath components by gas chro-
matographic (GC) analysis of exhaled air, and identified a wide
range of bloodborne volatile organic compounds (VOCs) ex-
haled after passing the blood/air interface within the lungs [2].
Also to the benefit of disease diagnostics, the scientific
and technological achievements during the 20th century have
brought numerous analytical diagnostic instruments to matu-
rity and have facilitated their implementation in the medical
sciences. Advanced diagnostic instruments such as electro-
cardiography (ECG), 3-D functional tomography (CT), and
similar technologies provide more accurate vital information to
medical doctors for precise diagnostic judgments on a patient’s
condition. Modern biomedical analytical instruments have
changed and matured with the medical sciences from empirical
to analytical strategies, and have assisted in broadening our
understanding on physiological processes from the molecular
level to cells, cell ensembles, and entire living organisms.
Consequently, it is of paramount importance to monitor phys-
iological processes associated with the human body for the
diagnosis of diseases or for assessing the health status. Unique
panels of molecular constituents may accompany certain physi-
ological processes or disease pathologies as mediators, markers,
or metabolic by- or end-products, etc. Hence, characteristic
biomarkers addressable with appropriate analytical techniques
have the potential for elucidating the corresponding physio-
logical processes, pathogenic pathways, or pharmacological
responses. However, usually such biomarkers are found only at
trace level concentrations within the human body.
Recent advances on the identification of disease biomarkers
have attracted considerable scientific and clinical interest in the
analysis of EB (vapor or condensate) providing a noninvasive
diagnostic window for diagnostic purposes. It is evident that
the composition of EB provides a complex image of the cor-
responding biochemical processes occurring within the body,
which may be correlated to the physiological status of a patient.
Hence, quantitative compositional analysis of breath may pro-
vide an attractive noninvasive diagnostic strategy for the recog-
nition, diagnosis, and status monitoring of complex diseases
and treatment strategies including but not limited to, e.g., breast
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cancer, lung cancer, and pulmonary diseases. However, quan-
titative analysis of breath metabolites present at nanomolar to
picomolar ( ) concentration levels in real
time remains a significant analytical challenge.
Nonetheless, it is evident that bodily secretions such as
urine or EB contain at least subsets or breakdown products of
biomarkers present within human body. In consequence, it is
highly desirable to establish sensing schemes with sufficient
sensitivity and molecular selectivity for addressing these con-
stituents noninvasively at trace levels. Gas chromatography
in combination with mass spectrometry (GC-MS) may be
considered the current golden standard method for analyzing
constituents relevant to breath diagnostics [3]. Despite excellent
sensitivity, GC-MS usually requires preprocessing of breath
samples and separation for addressing target analytes, which
renders this method less suitable for analyzing samples in real
time. While there are efforts in progress on miniaturizing GC
and MS components, to date this technology remains for most
applications confined to laboratory applications. In contrast,
mid-infrared (MIR) spectroscopy has proven an excellent
alternative methodology for trace level chemical detection
with high sensitivity and molecular selectivity. Compared
to GC-MS, MIR spectroscopy is appears more amenable to
miniaturization and integration, therefore promising close to
real-time analysis evaluating highly discriminative vibrational
and rotational molecular signatures, which are critical merits
for clinical applications on a routine basis.
The basic principle of the molecular level detection in the
MIR at possibly compact device platforms utilizes a broadband
light source or a tunable diode laser light source emitting radi-
ation in resonance with fundamental vibrational and rotational
modes associated with most inorganic and organic molecules
that are spectroscopically accessible within the MIR (3–20 )
regime of the electromagnetic spectrum. The interaction be-
tween MIR photons and particular organic molecules provides
– compared to the near-infrared (NIR) and the UV/Vis range
– comparatively sharp transitions. Despite the wide variety of
organic molecules, the unique sequence of absorptions reflect
the molecularly characteristic arrangement of chemical bonds
within the probed molecules via the frequency position of the
associated vibrational and mixed rotational-vibrational transi-
tions. The spectral absorption patterns in the MIR are also con-
sidered molecular fingerprints, therefore rendering MIR absorp-
tion spectroscopy a powerful sensing technique for trace level
chemical analysis.
II. BREATH ANALYSIS
The human body is considered among the most complicated
living organisms in nature. To sustain its function, a complex
metabolism progresses, which comprises a tremendous variety
of biochemical reactions. During such metabolic reactions, a
wealth of chemical/biochemical constituents are synthesized
or transformed. Such physiological reactions are well balanced
for within healthy human bodies, although there are variations
depending on each individual metabolism or physiological
status. As physiological reactions in response to diseases or
treatment are different from healthy subjects, the status or
progress of physiological and metabolitic processes should
reflect in concentration changes of key constituents involved
in or characteristic for specific reactions. While the majority
of such biomarkers remain located inside the human body pro-
viding access only via invasive sampling of blood or biopsies,
to a certain extent the pathophysiological condition should also
be reflected in the composition of excreted bodily fluids such
as urine, perspiration, saliva, etc., and breath as well as breath
condensate. Hence, it is not surprising that some of constituents
initially present with the human body may be determined
either natively or after metabolitic transformation within such
excretions. Each of these constituents may be considered a
potential biomarker providing valuable information on the
physiological status of the respective biological system, or the
progression of a disease and/or therapeutic treatment thereof.
However, given the complexity of such processes it has to be
anticipated that rather than individual biomarkers – which do
exist but are rarely sufficient for characterizing a physiological
condition – entire panels of biomarkers will be up- and/or
down-regulated during disease or treatment, yet above and
beyond any naturally occurring patient-to-patient variation.
Among these excretions, EB is considered a projection image
– particularly of the volatile – chemical constituent profile of
blood. While the alveolar membrane represents the interface
between blood and air, where the exchange of and
takes place. However, any other molecular component perme-
ating through this membrane barrier may finally be excreted
via EB, therefore serving as potential biomarkers. In addition,
EB contains nonvolatile compounds introduced via the lining
fluid of the bronchial tract, the oral cavity, and/or the sinus.
Among several advantages, diagnostics based on analyzing EB
from patients has the distinct advantage of noninvasiveness.
In particular, for patients in critical condition or neonates,
complementing or replacing invasive methods such as, e.g.,
biopsies by EB analysis provides an attractive alternative.
Furthermore, continuous access to naturally excreted samples
enables (close to) real-time monitoring of the patient condition,
which is difficult applying invasive testing and analyzing.
VOCs – and even less volatile constituents – are readily de-
tectable in EB using appropriate analytical instrumentation usu-
ally in combination with advanced sampling techniques [3]–[7].
The matrix of EB is predominantly composed of , , ,
and along with minute amounts of trace constituents. The
major constituents of EB reflect the inhaled breath composition
with few exceptions. The concentrations of and are
different before and after breathing due to the alveolar gas ex-
change. Furthermore, EB includes trace amounts of organic and
inorganic constituents permeating across the alveolar membrane
from blood into the gas phase as a result of metabolitic or normal
physiological processes, pathogenic processes, or a pharmaco-
logic response. While compact diagnostics for EB analysis still
remain in an early stage of research, there have been more than
1000 organic and inorganic constituents found in EB with con-
centrations ranging from the parts-per-million to the part-per-
trillion regime by volume. While the comprehensive relation-
ship between all the constituents in EB and the physiological
processes or diseases is not yet completely understood, some
diseases and the associated biomarkers detectable in breath are
well studied. For illustration, Table I summarizes a selection of
typical biomarkers and associated diseases.
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TABLE I
SELECTED DISEASES AND BIOMARKERS FOUND IN EXHALED BREATH AND EXHALED BREATH CONDENSATE
A. Exhaled Breath (EB)
VOCs present in blood reflect in EB due to permeation across
the alveolar membrane. The concentration of these VOCs will
be affected by many factors including, e.g., the composition
of inhaled breath, the concentration of VOCs in blood, and
the partition coefficients of each individual component. The
partition coefficient governs the relative concentration of each
VOC as it distributes at the breath-blood interface. For a
few VOCs, the partition coefficients at these conditions have
been studied. Among others, typical partition coefficients are
2100:1 for ethanol, 330:1 for acetone, and for
trichloroethylene [8]–[11].
The earliest and most extensively studied VOC in EB – with
respect to the motivation of disease diagnostics – is acetone [8],
[12]–[14]. Diabetes mellitus is a disease based on a metabolic
disorder resulting in an increase of glucose concentrations and
extensive lipolysis [15]. The liver produces ketones including
acetoacetate, 3- -hydroxybutyrate, and acetone, which are con-
sumed as substitute energy resources. Consequently, diabetes
induces increased blood ketones such that the concentration of
acetone increases up to an equilibrium determined by the ace-
tone partition coefficient across the alveolar membrane. Healthy
individuals usually have acetone concentrations of a few hun-
dred ppb in EB [14], [16]. In contrast, patients with diabetes re-
veal a considerable range of acetone concentrations in EB – as
determined, e.g., by gas chromatography – depending on several
parameters including the type of diabetes, age, sex, physiolog-
ical status, etc.
As another example, the -urea breath tests (UBT) uti-
lizing isotope labeling is a common method for detecting Heli-
cobacter pylori infections in the stomach via the
ratio. Such methods are suitable for detecting bacterial coloniza-
tion and metabolism related to the gastroenterological system,
pancreas, and liver [17]–[21]. Helicobacter pylori are known to
cause gastric ulcers, duodenal ulcers, heart disease, and gastric
cancers [22]–[24]. Orally administered -labeled urea is hy-
drolyzed by Helicobacter pylori in the stomach of the patient.
This process produces ammonia and labeled , which
diffuses into the blood matrix, and eventually shows up in EB
where it can be used for Heliobacter infection diagnosis.
A variety of VOCs have been analyzed to diagnose respira-
tory infection and inflammation. Nitric oxide (NO) is a widely
studied biomarker in EB, and serves as a nonspecific marker
of inflammation in the lungs [5], [25], [26]. Also, NO is in-
creased in atopic asthma and chronic obstructive pulmonary dis-
ease (COPD), but decreased in cystic fibrosis (CF) [27]–[30].
CO in EB was first studied as a potential biomarker in 1972
[31]. The major origins of CO in EB are categorized by exoge-
nous processes, haem degradation, and nonhaem endogenous
processes such as, e.g., lipid peroxidation or bacteria. CO in EB
is also reported to increase in asthma, COPD, and CF [32]–[34].
and pentane indicating peroxidation of polyunsaturated
fatty acids were founded in EB from patients suffering from
schizophrenia [35], [36]. However, the endogenous origin of
, a potential specific biomarker for schizophrenia, is still
unknown.
Last but not least, lung cancer appears detectable via different
combinations of VOCs including, e.g., C4 to C20 alkanes, and
monomethylated alkanes [37]. Below, we will discuss the rele-
vance of VOCs in EB for breast cancer diagnosis [37]–[40].
B. Exhaled Breath Condensate (EBC)
Nonvolatile constituents in EB may also serve as potential
biomarkers. While VOCs in EB mainly reflect the biochemical
profile of blood, nonvolatile compounds predominantly in
EBC are largely associated with biochemical changes of the
surface lining fluids in the breathing airways starting from the
alveoli to the nose and mouth. EBC is usually collected by a
device with a cooled collection surface enabling condensation
[5]. Depending on the collection conditions and the condenser
temperature also some VOCs may be collected within EBC.
In general, the composition of EBC has been less studied
than, e.g., VOCs in EB. For example, elevated levels of ,
leukotrienes, lipid peroxidation products, and isoprostanes in
EBC were reported from patients with asthma, COPD, or CF
[41], [42]. These constituents are considered oxidative stress
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biomarkers. Nitric oxide metabolites such as, e.g., S-nitrosoth-
iols, nitrite, nitrate, and 3-nitrotyrosine in EBC have also been
used as trace compounds of airway inflammation in asthma,
CF , COPD, and acute respiratory distress syndrome (ARDS)
[43]–[46]. Since the stability and reactivity of many reactive
oxygen and nitrogen species are dependent on the pH, the
actual pH of EBC is also an indicator of, e.g., reactive oxygen
or nitrogen species. For asthma, a relationship between the pH
of EBC and asthma severity was observed, while in CF patients
a lower pH of EBC was associated with exacerbations [47].
Furthermore, adenosine – which is a metabolite of adenosine
triphosphate degradation – elicits a broad range of effects via
specific receptors. Hence, elevated EBC adenosine levels have
been determined as useful indicators in patients with allergic
rhinitis and asthma [48]–[50].
C. VOC Analysis for Noninvasive Breast Cancer Detection
Worldwide, breast cancer (BC) is both the most commonly di-
agnosed cancer among females and the most common cause of
female cancer death. However, marked disparities in incidence,
stage at diagnosis, tumor aggressiveness, treatment, and mor-
tality exist at the global level [51]. Once considered a disease
of affluent western nations, breast cancer incidence and mor-
tality rates are rapidly increasing in most developing countries
where detection and treatment options remain grossly inade-
quate [52]–[57]. Stage at diagnosis remains the most important
BC predictive and prognostic factor, i.e., earlier stage detection
results in more treatment options and better prognosis [58], [59].
Mammography screening remains the gold standard for early
stage detection and resultant improved outcome, including de-
creased mortality. Presentation at very late disease stage is the
major BC problem in most developing countries, where wide-
spread use (or any use) of mammography is precluded by the
lack of financial and technical resources. Furthermore, a higher
risk for breast cancer and more aggressive tumors are observed
in certain subpopulations [57], [60]–[68]. Finally, for women
diagnosed with breast cancer, whether in technologically ad-
vanced areas or developing countries, there is an evident need
for monitoring devices following treatment [57], [64], [69]. The
lack of mammography in developing countries, the necessity for
interval/more frequent screening for higher risk women or those
at risk for more aggressive cancers at earlier ages, and the role
of monitoring for reoccurrence in treated breast cancer patients
demonstrate the crucial need for alternative screening methods
in the United States and throughout the world.
The use of breath volatile organic constituent (BVOCs) anal-
ysis has a significant potential to meet these needs. The use
of EB as a noninvasive cancer screening modality is receiving
more and more attention, particularly for lung cancer. We have
recently demonstrated the feasibility of using a simple sam-
pling device (commercially available Markes Bio-VOC sam-
pler combined with a rapid passive sampler) and gas chromato-
graphic/mass spectrometric (GC/MS) analysis to differentiate
BVOC patterns between healthy and breast cancer patients in
a study of 20 healthy volunteers and 20 cancer patients [70].
During this study, we have substantiated the hypothesis that
there is a link between the presence of breast cancer and the oc-
currence of certain BVOCs, and that a simple sample collection
device and mass spectrometric analyses could adequately indi-
cate the presence of this link. To investigate this relationship,
the alveolar breath of each subject was collected by the sub-
ject breathing five times at five-minute intervals into the sampler
containing a Radiello® passive sampler followed by analysis via
thermal desorption/GC/MS (TD/GC/MS). Background air was
collected passively with Radiello® samplers placed in the room
during the breath sample collection time-period to measure po-
tentially confounding atmospheric exposures by the subjects in-
haling volatile organic compounds (VOC) during the sampling
period. Each subject refrained from eating or drinking for 2 h
prior to sample collection to minimize confounders as a result
of recent food and beverage ingestion. A total of 383 BVOCs
were identified in the breath in both subpopulations – control
and cancer. Several of these compounds may originate from
lipid peroxidation mechanisms, i.e., nonenal, hexenal, hexanal,
methacrolein, and isoprene. These compounds were grouped
according to chemical properties and then – using both iden-
tity and concentrations – used as the input into a nonlinear re-
duction procedure for classification analysis. We achieved an
overall sensitivity of 72%, and a specificity of 64% resulting in
a correct classification rate of approximately 77% for differen-
tiating breast cancer cases from no cancer [70]. These percent-
ages are derived from 10,000 simulations involving random par-
titions into training and validation subsets within the observed
data. BVOC biomarker patterns were obtained by monitoring
383 BVOCs among all of the volunteers. The available data was
randomly split into two subsets: training and validation. Each
training sample consisted of 60% of case observations and 60%
of control observations, thus leaving 40% of cases and 40% of
controls for testing the performance of classifiers. This simu-
lation task was repeated 10 000 times using different randomly
selected training and validation sets. Performance results were
averaged over all runs.
In conformance with other researchers, our results indicate
that individual compound identification is not appropriate for
determining the presence or absence of disease, but aggregate
low-dimensional summaries and compound quantities result
in specific patterns that can confirm disease. Our data show
promising evidence that breast cancer patients can be differen-
tiated from volunteers through distinct BVOCs. Furthermore, it
clearly demonstrated that predictive screening may be possible
with this innovative approach.
D. VOC Analysis for Exposure Monitoring
An area where breath analysis has a tremendous potential,
though which has only been partially tapped is personal expo-
sure monitoring [71]. Breath analysis for exposure monitoring
has the advantage of being able to measure body burdens
thereby providing data about the relationship between exposure
and dose [72]. The TEAM studies demonstrated that exposure
may not be closely related to emissions, thereby demonstrating
the need for personal exposure monitoring and means to
measure body burdens [72]–[75] found that for EB VOCs to
be an effective and sensitive method to determine exposure
body burdens. Their findings demonstrated that exposure VOC
breath levels in known exposure level tests were predictable
and reproducible across their volunteer population. Xu et al.
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[76] successfully measured the dermal uptake of 1,1-dichloro-
propanone 1,1,1-trichloropropanone, and chloroform during
showering by analyzing time concentration profiles via EB
samples. The breath VOCs in 26 asthmatic Hispanic children
living near major freeways and trucking routes were deter-
mined by Delfino et al. [77]. Eight VOCs were quantified in
greater than 75% of the samples: benzene, methylene chloride,
styrene, tetrachloroethylene, toluene, -xylene, -xylene,
and -chlorobenzene. Their results showed a weak association
between exhaled benzene and asthma episodes.
VOCs exposure in occupational settings are important
sources of adverse health impacts due to the potentially higher
the ambient levels due to large-scale production, their use in
manufacturing processes, and their high toxic potential. The
biomonitoring of occupational VOCs exposures is important
to identify dose-response effect before toxic effects are man-
ifested. Breath analysis is one biomonitoring technique that
has been applied to measure occupational VOCs exposures.
Amorim et al. [78], [79] used the Bio-VOC sampler with
solid-phase microextraction (SPME) for sample collection
and concentration to measure benzene in breath of workers at
gasoline stations and a control group. They detected an average
benzene level of 8.2 ppb in the control subjects and 25.3 ppb in
the gasoline station workers. Chen et al. [80] also used breath
VOCs and personal exposures of gasoline station workers to
determine the breath VOCs sources. They measured toluene,
xylene and ethylbenzene the breath of 30 workers from 10
gasoline stations. The study of Chen et al. suggests that exhaled
toluene and xylene levels are suitable for use as biological
exposure indices even at the ppb-level of exposure.
E. Sampling Methods for EB Vapor
The majority of the current methods used for breath analysis
have involved collection of the breath samples on an adsorbent
media or in an evacuated canister followed by GC/MS analysis
[81]. Pellizzari et al. [82] published a standard method for mea-
suring VOC exposures via EB by having the subject breath into
a Tedlar bag and then drawing the air onto a Tenax cartridge
followed by GC/MS analysis. A spirometer mouthpiece was
used to collect the alveolar exhaled air. Lin et al. [83] analyzed
volatile carbonyl compounds in breath to investigate lipid per-
oxidation by collecting the breath samples on silica cartridges
impregnated with 2,4-dintrophenylhydrazine (DNPH) with high
pressure liquid chromatographic (HPLC) analysis. The subjects
breathed into a Douglas bag from which the trapped breath was
drawn onto the sampling cartridges.
The frequently used adsorbent media is one method of
preconcentration used to date by most researchers of breath
VOCs. The very low concentrations of many breath com-
ponents (low ppb or lower range) necessitate enrichment to
achieve detectable sensitivity for the analytical techniques [84],
[85]. Organic polymers, activated charcoal, graphitized carbon,
carbon molecular sieves, cryogenic trapping, and solid phase
microextraction (SPME) are all methods that have been em-
ployed to preconcentrate a larger volume of sample to achieve
detectable analytical sensitivities. Each of these methods apply
technique biases and for the most part focus a large number
of compounds somewhat equally rather than allowing the
targeting of selected compounds of interest.
F. Direct Analysis of EB
Direct analysis of EB (vapor or condensate) is among the
major challenges in breath diagnostics due to more than 1000
constituents found in EB. Their concentration ranges from the
part-per-million (ppm) to the part-per-trillion (ppt) regime,
which renders only few analytical techniques suitable to assess
these compounds at trace levels including, e.g., gas chromatog-
raphy (GC), mass spectrometry (MS), infrared spectroscopy,
and chemiluminescence. GC – in part – in combination with
MS – is probably the most common method to analyze breath
relevant constituents at trace levels. L. Pauling has already used
GC techniques to investigate human EB [2]. While GC can
cover a wide variety of compounds with excellent sensitivity,
it remains a rather sophisticated method usually bound to the
laboratory, and of limited suitability for real-time analysis.
Several different types of and combinations with MS also
provide high sensitivity, but are likewise bulky and expensive to
operate. Both techniques are highly suitable – and probably the
gold standard – for laboratory studies, however, lack in practi-
cability during everyday use in clinics or during field studies.
Consequently, portable breath analyzers should be compact
in size, enable – at least close to – real-time measurements,
inherently trace multiple biomarkers, remain cost effective,
and provide the demanded molecular selectivity and sensitivity
at ppb to ppt (by volume) concentration levels. Hence, direct
analysis methods of breath VOCs offer significant advantages.
Complications of contamination from sampling media/systems,
the loss of VOCs by adsorption onto the storage vessel, and/or
collection biases resulting from the selection of the adsorbent
media are reduced. Additionally, immediate results are at-
tainable with direct analysis methods rather than waiting for
the sample to returned to a laboratory for analytical analyses.
Selected ion flow tube mass spectrometry (SIFT-MS) is one
of the more commonly used direct analysis method for breath
VOCs analysis [86]–[89]. Although SIFT-MS has been applied
to breath analysis in real-time without the need for preconcen-
tration, this instrument is a highly specialized type of mass
spectrometer and is not readily available in many laboratories,
particularly clinical laboratories; therefore, does not have wide
applicability for population exposure studies. Proton transfer
reaction mass spectrometry (PTR-MS) is another specialized
mass spectrometer that allows the direct, real-time measure-
ment of breath [90]–[92]. Once again this is an uncommon
and expensive laboratory-based mass spectrometer that is not
readily available in many laboratories; therefore, does not have
a significant applicability for population exposure studies.
Electronic nose technology also has been applied to breath
analysis; however, these generally have the drawback of nonse-
lectivity [93]. Di Natale et al. [94] used an electronic nose con-
sisting of eight quartz microbalances coated with different met-
alloporphyrins to investigate if breath VOCs could detect lung
cancer by focusing on alkanes and aromatic compounds. Breath
was collected from the subjects in a sampling bag from which
the analysis was performed. Overall, using this analytical tech-
nique in conjunction with a biostatistical classification scheme
was able to differentiate between cancer and noncancer in 94%
of the cases.
In summary, the examples of noninvasive breast cancer de-
tection discussed in , and exposure monitoring summarized
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Fig. 1. Schematic of a measurement setup using an IR broadband (e.g., FT-IR)
or IR narrowband (e.g., laser) light source for direct absorption gas sensing.
IR radiation is selectively absorbed by analyte molecules within the absorption
path defined by a single-pass gas cell, multipass gas cell, or hollow waveguide.
A reference channel with a reference detector may be introduced, if a laser light
source is used. (MCT— mercury-cadmium–telluride detector.)
in clearly indicate the need for portable sensing devices
that are particularly capable of either direct or preconcentrated
VOC detection. Therefore, the inherent molecular selectivity
provided by MIR spectroscopic and sensing techniques promise
an interesting suite of measurement techniques for advanced EB
analysis.
III. MID-INFRARED (MIR) SENSING TECHNIQUES
MIR spectroscopy provides a sensing platform that appears
ideally suited to fulfill the needs of clinically deployable
breath analyzers with respect to the criteria listed above. In
the following, this contribution reviews and compares various
emerging MIR sensing techniques based on the types of MIR
radiation sources and transduction principles with respect to
their potential suitability for breath analyzer applications. Fig. 1
provides a general measurement scheme for IR absorption gas
sensors.
A. Mid-Infrared (MIR) Light Sources
1) Sensing Based on Broadband MIR Light Sources: Fourier
transform infrared (FT-IR) spectrometers combined with an
appropriate gas cell establish a broadband MIR gas sensing
system. SiC filaments used in FT-IR spectroscopy emit (black
body) radiation covering the entire MIR range. In combination
with hollow waveguide gas sensing modules, Mizaikoff and
his research group have demonstrated sensitive detection of
and with limits of detection (LOD) of 15.8 and
517 ppb utilizing such broadband sensing systems, i.e., a 1 m
long hollow core waveguide (HWG), and a mercury cadmium
telluride (MCT) detector [95]. The volume requires to fill the
gas cell is only approx. 1.5 mL, which appears ideally suitable
for, e.g., EB analysis. The general advantage of broadband MIR
sensing systems is the wide spectral coverage so that most of
the VOCs in EB can be assessed via their molecularly selective
absorption signatures. However, the rather weak spectral energy
density provided by this broadband emitter – in particular, in
contrast to laser light sources – limits the achievable sensitivity.
In addition, the obtained spectra frequently appear highly con-
voluted due to the anticipated complex molecular composition
of the sample, which demands for sophisticated multivariate
data evaluation and calibration techniques.
2) Sensing Based on MIR Laser Light Sources: In contrast to
broadband emitters, MIR laser sources provide enhanced spec-
tral density in a narrow emission band, which should facilitate
target constituent analysis at trace concentration levels. While
high spectral power density is a significant advantage for en-
hanced sensitivity, the lasing wavelength is usually fixed or may
only be tuned across a narrow spectral range, thereby trading off
some multiconstituent sensing capability. MIR laser sources in-
clude rather bulky gas lasers such as, e.g., lasers (
) and CO lasers ( ), devices for nonlinear
optical wavelength conversion, and narrow bandgap semicon-
ductor lasers and quantum cascade lasers (QCL). Though gas
lasers provide the required MIR radiation for absorption spec-
troscopy, they have a few drawbacks such as complexity of op-
eration, bulky dimensions and footprint, and limited tunability.
Therefore, sensing systems based on gas lasers are predomi-
nantly limited to laboratory usage.
Wavelength conversion techniques generate MIR radiation
by converting a fundamental pump beam of a visible or near-in-
frared (Vis/NIR) laser into radiation at MIR frequencies via
nonlinear optical processes. Optical crystals with no structural
inversion symmetry are able to generate such converted elec-
tromagnetic radiation ( , idler) from a pump beam ( , pump)
with/without another input beam ( , signal) taking advantage
of the second-order nonlinear optical coefficient ( ). This
process is referred to as difference frequency generation (DFG)
with as external input, or optical parametric oscillation
(OPO) without as external input, respectively. The main
advantage of frequency down conversion is the fact that ma-
ture Vis/NIR laser sources are readily available providing the
required output power, beam quality, etc. Such arrangements
may even convert Vis/NIR radiation into MIR radiation where
compact or high-power coherent light sources were not avail-
able until the advent of QCL technology in 1994 [96]. For
example, the research group of Tittel has developed compact
laser different frequency spectrometers for multicomponent
trace gas detection [97]. The sensing system based on this
principle utilizes a periodically poled lithium niobate (PPLN)
crystal as a nonlinear optical medium, which is pumped by
a Nd:YAG laser (1064 nm, 700 mW), and a widely tunable
external cavity diode laser ( , 16 mW). Thus,
an output frequency range from 3.98 to 4.62 may be
covered. With this DFG spectrometer sensitivities down to 2
ppb for , 5 ppb for CO, and 100 ppb for have been
achieved [97].
Narrow Bandgap Semiconductor Lasers: While sensing
systems equipped with gas lasers or conventional solid state
lasers demonstrate excellent sensitivity owing to their high spec-
tral power density, their bulky dimensions and limitations in
tuning the emission range still limits their applicability, e.g.,
in clinical settings. Hence, it is essential to develop sensing
systems based on more compact sized laser light sources en-
abling broad tenability of the MIR emission. The main develop-
ment efforts for MIR laser sources have been focused on narrow
bandgap semiconductor materials including, e.g., lead salt ma-
terials or IV-VI semiconductors, and were encouraged by the
success of compound semiconductor lasers in the Vis and in
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the NIR regime. These narrow bandgap semiconductor lasers
operate by generating photons via radiative recombination of
electrons from the conduction band, and holes from the valence
band. Narrow bandgap lasers have been used as MIR sources
within a wide variety of sensing studies with only few selected
application examples illustrating their utility in breath-related
applications here. For example, Roller et al. have utilized a
IV-VI MIR laser to simultaneously determine exhaled NO and
in human breath for quantitatively discriminating between
asthmatic and nonasthmatic exhalations [98]. In another study,
Jeffers et al. have measured benzene in air with a detection limit
of 1 ppm by volume, and an integration time of 4 s [99].
Narrow bandgap semiconductor lasers have several disad-
vantages, even though they represent a family of compact MIR
laser sources. Most importantly, they usually require cryogenic
temperatures (15–80 K) for operation at acceptable output
power. Yet, their optical power remains low, i.e., in the range
of several milliwatts and below. In addition, the achievable
beam quality is limited and frequently inconsistent between
laser diodes. Finally, they are limited in achievable emission
frequency within the MIR spectral band, as the emission wave-
length is largely governed by the bandgap provided by the
involved material, which is difficult to engineer. In particular
the need for cryogenic cooling adds to the complexity of a
sensing system, and limits applicability in real-world scenarios.
Furthermore, comparatively low optical output power as pro-
vided by narrow bandgap lasers limits the detection sensitivity
of the sensing system to biomarkers present or changing their
concentration at relatively high concentration levels (high ppb
to ppm range).
Quantum Cascade Lasers: Most of the limitations associ-
ated with narrow bandgap semiconductor lasers are overcome
by the latest generation of semicinductor laser light sources,
namely quantum cascade lasers. QCLs emit photons by suc-
cessive radiative intersubband transition of electrons within
the conduction band without contribution from radiative re-
combination of electrons and holes. Resulting, intentional
tailoring of the laser emission frequency is simply achieved by
engineering the thickness of the layers composing the quantum
heterostructure, rather than changing the composition. In ad-
dition to thus achieved flexibility in laser emission frequency
selection, QCLs inherently provide significantly higher optical
output power [100] exceeding 700 mW [101], whereas lead
salt lasers usually emit only a fraction of this power (e.g., at
1.2 mW [102]) in multimode continuous wave operation [103].
Since the introduction of QCLs in 1994, numerous studies have
demonstrated superior sensitivity and selectivity achievable
utilizing this most advanced MIR light source for gas sensing
applications in dependence of the type of gas cell that has been
used, and the tunability of the QCL. For example, Charlton et
al. have reported the detection of 30 ppb ethyl chloride within
a 1.5 mL sample volume based on an integrated MIR sensing
system utilizing a 1 meter long photonic bandgap fiber, and a
QCL lasing at a wavelength of 10.3 [104], which expands
previously reported results into the low ppb concentration range
[105], [106].
Tunable Quantum Cascade Lasers: Application of a laser
light source for biomarker detection in breath analysis has
an advantage, if sensitive and molecularly selective detection
can be achieved via frequency matching between the laser
emission, and the absorption of a particular analyte. Most
frequently, this match is not naturally achieved; therefore, the
ability to precisely and deliberately tune the laser emission
across a selected spectral range is of particular importance.
Conceivably, an array of widely tunable QCLs could cover
a range of hundreds of wavenumbers within the MIR band,
therefore establishing a “miniaturized spectrometer” based on
a series of QCLs, thereby quantitatively addressing a variety
of different biomarkers within a breath sample. Initial methods
to achieve QCL emission tuning have included adjusting the
heat sink temperature using a cryostat, or using DC laser injec-
tion currents [107]–[109]; however, the spectral tuning range
remained limited to a few wave numbers. Other approaches
aim at tailoring the laser emission include the fabrication of an
array of single-mode lasers monolithically fabricated on one
chip with a variety of emission frequencies [108], or tailoring
the cavity length of the QCL [110]. Perhaps the most effective
method for widely tuning QCL emission frequencies has been
the combination with or integration of external cavities, which
are commonly known as external cavity quantum cascade
lasers (EC-QCL). External cavity tunable QCLs (EC-QCLs)
[111]–[115] operate by changing the angle of an external
diffraction grating, which creates single mode emission via fre-
quency selective feedback [100], thereby continuously tuning
the laser emission across a spectral range determined by the
properties of the grating; such devices may cover to date up
to 250 [113]. A recent study by Young et al.. presents
selective and sensitive simultaneous detection of multiple ana-
lytes within a gaseous sample at ppb cocentration levels [116].
Using an EC-QCL combined with a hollow waveguide trace
gas sensing module enabled precisely tuning the laser emission
to selective absorption frequencies within a mixture of three
gases, thereby simultaneously detecting these constituents
at concentrations as low as 4 ppb for ethyl chloride, 7 ppm
for dichloromethane, and 11 ppb for trichloromethane during
exponential dilutionexperiments.
B. Transducers
1) Hollow Core Waveguides Versus Conventional Gas
Cells: Quantitative direct absorption measurements rely on
the Lambert–Beer law ( with ,
, , and
). Hence, controlling the sensitivity of
the device is largely based on selecting an appropriate optical
path length, i.e., in most cases the length of the gas cell. As a
result, the internal volume of a gas cell usually has to be large,
such that the required optical path length for low detection
limits may be achieved by folding the beam multiple times
within the sample volume (Fig. 2). Such multipass gas cells
offer enhanced sensitivity due to mirrors within the cell, which
fold the IR beam for extending the optical path length up to
several 100 m; however, the internal volume of such gas cells
may reach 3 liters or more, which adversely affects the response
time to concentration changes, and occasionally – e.g., in EB
analysis – requires prohibitively large sample volumes [56].
Thus, gas cells with smaller internal volumes that still retain
or improve the achievable sensitivity by ensuring intimate
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Fig. 2. Schematic of a measurement setup using an IR broadband (e.g., FT-IR)
or IR narrowband (e.g., laser) light source for direct absorption gas sensing with
a multipass gas cell. A reference channel with a reference detector is optional,
if a laser light source is used. (MCT—mercury-cadmium–telluride detector.)
Fig. 3. Schematic of a measurement setup using an IR broadband (e.g., FT-IR)
or IR narrowband (e.g., laser) light source for direct absorption gas sensing using
a hollow waveguide. The hollow waveguide simultaneously acts as a gas cell and
as a light pipe propagating IR radiation, thereby ensuring intimate contact be-
tween IR photons and analyte molecules within the hollow core. A reference
channel with a reference detector is optional, if a laser light source is used.
(MCT—mercury-cadmium–telluride detector.)
interaction between photons and molecules are required for
taking full advantage of QCL-based chemical sensors for the
detection of biomarkers in human breath.
A potential solution to these demands are hollow waveguide
(HWGs) structures (Fig. 3). Such structures may be as simple
as a structural silica tube, which is internally coated with a re-
flective layer of silver followed by a thin protective layer of
silver iodide [117], or more sophisticated, a hollow core struc-
ture with cylindrical layers of, e.g., glass and polymer materials
exhibiting alternating dielectric constants, which create a pho-
tonic bandgap [104], [108], [118] (termed photonic bandgap
waveguides; PBG). QCL-based optical chemical sensors uti-
lizing hollow waveguides have already demonstrated limits of
detection down to a few ppb [104], [108] probing an internal
volume (within the HWG or PBG) of only a few milliliters; such
volumes appear advantageous for biomarker detection in breath.
Furthermore, it is conceivable that coiled HWGs may be used
for even further extending the achievable optical path length, al-
though a balance between the benefits of the enhanced optical
Fig. 4. Schematic of a measurement setup using a modulated IR broadband
(e.g., FT-IR) or IR narrowband (e.g., laser) light source for photoacoustic gas
sensing. Modulated IR radiation periodically heats the sample gas, thereby pro-
ducing a pressure wave detectable at acoustic frequencies as a function of ana-
lyte concentration.
interaction path length, and radiation losses from bending the
waveguide has to be determined [119].
2) Photoacoustic Transducers: Photoacoustic spectroscopy
(PAS) [120] is another sensing technique that has been inte-
grated with QCLs for trace gas sensing. PAS has the distinct
advantage over other sensing technologies described herein that
the signal transduction is not based on absorption, rather than
pressure changes induced in a resonant or nonresonant sample
compartment by modulated MIR radiation generating molec-
ular vibrations (Fig. 4). The occurring fluctuations in pressure
create a sound wave, whose intensity is a direct function of
the gas concentration [100]. QCL-based PAS systems (QCL-
PAS) conventionally use a device as simple as a microphone
for transducing the sound wave, as documented during several
studies with ultra-low sensitivity at ppb to parts-per-trillion (ppt)
levels [121]–[124]. For example ammonia, which is considered
a biomarker for asthma [5], was detected down to 66 ppb using
QCL-PAS [122]. Most recently, a quartz tuning fork has been
used in lieu of a microphone as the detector resulting in a tech-
nique known as quartz enhanced photoacoustic spectroscopy
(QEPAS). Here, the resonance frequency of a quartz tuning fork
is affected by the pressure fluctuations and resulting acoustic
wave, if the probed molecules are present in between or close
to the arms of the tuning fork. The major advantage of QEPAS
with respect to the detection of biomarkers in breath is that the
dimensions of the tuning fork are small (e.g., quartz tuning forks
as used in conventional quartz wrist watches have been used
for QEPAS), thus achieving ultra-low sample volumes down
to . In turn, this small volume allows for an overall
miniaturized sensor footprint (approx. 5 are typical di-
mensions), which is particularly important for handheld diag-
nostic applications [125].
3) Solid Core Waveguides: In solid core waveguides, MIR
radiation interacts with analyte molecules via an evanescent
field, which may be generated at the interface between wave-
guide and adjacent medium, if appropriate optical conditions
are provided (i.e., a waveguide with higher refractive index than
the surrounding medium). Thus, solid core waveguides or solid
core optical fibers may serve as efficient optical transducers en-
suring reproducible interaction between photons and molecules
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Fig. 5. Schematic of a measurement setup using an IR narrowband (e.g., laser)
light source for liquid phase (e.g., breath condensate) evanescent field absorp-
tion sensing using a planar waveguide (PWG). A condensate sample is deposited
onto the surface of the PWG, and analyte molecules present within the penetra-
tion depth of the evanescent field selectively absorb radiation at molecule-spe-
cific frequencies. A reference channel with a reference detector is optional, if a
laser light source is used. (MCT—mercury-cadmium–telluride detector.)
at the waveguide surface, which may be modified in addition
with analyte enrichment membranes or molecular recognition
(bio)chemistry for attracting the probed molecules to the trans-
ducer surface. Of particular importance for MIR sensors is the
surface modification with polymer membranes, which may not
only enrich target analytes for detection with enhanced sensi-
tivity, but may also selectively exclude a background matrix
such as, e.g., liquid phase water from the analytically probed
volume determined by the exponentially decaying evanescent
field. Recently, Mizaikoff and collaborators have reported on
the first liquid phase MIR sensing system comprising a QCL
coupled with a thin film planar silver halide waveguide, and a
QCL coupled to the first planar single mode MIR waveguide
microfabricated from GaAs/AlGaAs, which is considered
the first step towards fully integrated on-chip/on-wafer MIR
photonic sensing systems [126], [127]. Based on such waveg-
uides the detection of 80.7 of precipitated solid urea at the
planar waveguide surface, and of 10.8 of acetic anhydride
in solution (0.01 of acetonitrile) has been shown. Solid
core planar waveguides are considered ideal candidates for EB
condensate analysis, although their application is not limited to
liquid phase or solid phase constituents (Fig. 5).
IV. BREATH DIAGNOSTICS WITH MIR SENSORS:
POTENTIAL AND CHALLENGES
In the previous sections, the potential of biomarker panels
found in EB (vapor and condensate) has exemplarily been
highlighted, and the need for noninvasive diagnosis (e.g., in
breast cancer screening) with particular reference to MIR spec-
troscopic and sensing techniques, which are capable of directly
addressing relevant molecular signatures at trace levels, e.g.,
for VOCs has been discussed. Hence, detecting biomarkers
in EB (vapor and condensate) using MIR sensing techniques
possibly in combination with complementary sensing devices
appears to provide an interesting strategy toward next-genera-
tion diagnostics in this emerging field.
A. Application of MIR Sensors in Breath Analysis
When considering the practical requirements for applying
breath analyzers in the field, it is evident that MIR spectroscopic
sensors are among the most promising technologies facilitating
clinically deployable breath analyzers. In general, several of
the MIR sensing systems discussed previously have initially
been developed for the detection of trace level gaseous con-
stituents in a wide variety of application scenarios. However,
the exclusive molecular selectivity inherent to this frequency
regime, the achievable detection limits, and the potential for
miniaturization and integration suggests that this technology
may significantly impact the field of breath diagnostics, which
demands similar requirements.
Very recently, few academic and industrial studies have re-
ported on translating IR technologies into devices suitable for
breath analysis.
For example, Roller et al. have reported on the application of
sensing systems utilizing tunable laser absorption spectroscopy
(TLAS) to detect approximately 30 ppb of carbonyl sulfide
(COS), which is considered a biomarker for failure of liver
function, and for acute lung transplant rejection [128]. The
TLAS sensing system comprised a thermoelectrically cooled
MIR QCL lasing at 4.86 , and a 36 meter long optical
multipass gas cell.
In another example, QCLs have been used as light source
in integrated cavity output spectroscopy (ICOS) for detecting
down to approx. 3.6 ppb NO during studies involving 15 ex-
haled human breath samples [129]. Ekips Technologies, Inc. has
reported on the development of a tunable diode laser absorption
spectroscopy (TDLAS) system utilizing IV–VI narrow bandgap
semiconductor laser diodes emitting at 5.2 in combination
with a 107 meter long multipass White cell for addressing ex-
haled NO and [98]. The Ekips TDLAS sensing system was
successful in discriminating asthmatic subjects from nonasth-
matic subjects by the elevated level of exhaled NO. Further-
more, they have applied the TDLAS sensing system to studies in
veterinary medicine during clinical trials of up to 800 subjects
[130].
While clinical trials using MIR sensing techniques are yet
rare, it appears that initial efforts and results are encouraging and
should trigger further evaluation of this promising technology in
breath diagnostics.
B. Challenges, Potentials, and Future of MIR Breath Analyzers
In the opinion of the authors, the main challenges for estab-
lishing clinically deployable MIR breath analyzers are twofold:
i) development of MIR sensing systems reliably operating
at ppb/ppt concentration levels and ii) identification of VOC
biomarker panels traceable with MIR diagnostics.
Although the concentration of VOCs in EB (vapor and
condensate) ranges from ppm to ppt levels, the sensitivity of
the most practically applicable MIR sensing system remains at
few tens of ppb. This sensitivity level currently limits access
to biomarkers occurring at ppt concentrations, which would
significantly broaden the spectrum of addressable VOCs in EB
from currently only a handful of VOCs to an entire diagnostic
panel. While device miniaturization is well on the way, the per-
formance has to be enhanced for routinely addressing sub-ppb
concentration levels. The advent of QCLs has tremendous
impact on the utility and compactness of MIR sensing systems,
and may be considered the single most important breakthrough
for MIR technologies. However, of equal importance is the de-
velopment of appropriate transduction schemes, i.e., waveguide
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technologies, for ensuring efficient, reproducible, and quanti-
tative interaction of photons with the molecular constituents.
With the advent of the first semiconductor waveguides propa-
gating MIR radiation for liquid, solid, and gas phase analysis
a significant step forward toward compact sensing devices is
evident. Eventually, handheld device dimensions pave the way
toward personal health monitoring devices for direct in situ
monitoring of the physiological status; clearly, IR technologies
may be a vital component of such monitoring devices in com-
bination with complementary sensing strategies. In addition,
given the rather strong molecular absorptions of water vapor,
MIR sensing schemes have to either minimize the impact of
water vapor during the measurement by selecting appropriate
spectral windows or tunable light sources, and/or take advan-
tage of multivariate data evaluation schemes for deconvoluting
the spectral contributions of water vapor and the constituents of
interest. However, this is a general problem associated with IR
spectroscopic measurement techniques, and has widely been
addressed with a variety of strategies [131].
To date, breath analysis is still largely relying on single or few
biomarker(s) detection, and the effort to attribute a certain con-
dition to such few constituents, while human EB (vapor and con-
densate) is a complex matrix comprising more than 1000 VOCs.
Hence, advanced EB diagnostics should take advantage of this
wealth of information by addressing multiple constituents in
parallel for accessing the physiological status of patients with
more fidelity. This is of particular importance for complex dis-
ease pathologies, as encountered for various cancers detectable
via breath, such as, e.g., lung cancer and breast cancer. Tracing
the up- and down-regulation of individual constituents within
entire biomarker panels is therefore a primary goal for next-gen-
eration diagnostic devices, however, requiring that fundamental
research into, e.g., VOC panels characteristic for a certain dis-
eases – as discussed for the case of breast cancer – remains a
vital research area. In combination with state-of-the-art com-
putational data analysis techniques and signal processing such
massive data sets may be compressed to the characteristic vari-
ables relevant for certain disease pathologies, thereby defining
the fundamental needs and demands for subsequently developed
sensing technology.
In addition, continuous efforts into researching the medical
relevance of VOCs is in demand, as only a few VOCs including,
e.g., acetone or NO and their metabolitic importance are well
understood, while the role of most VOCs remains ambiguous.
For example, biomarkers such as and their relationship
with, e.g., schizophrenia are only in part understood lacking in
depth understanding on the involved physiological processes.
However, even if breath diagnostics come the proposed long
way toward practical usage, precise interpretation of the ob-
tained results ultimately relies on a thorough understanding of
the underlying physiological importance.
Future efforts in developing next-generation breath diagnos-
tics – and in particular – devices taking advantage of the inherent
molecular selectivity associated with MIR sensing techniques –
will have to overcome the diagnostic challenges described above
including the technical challenges of reliable quantitative op-
eration at the required levels of sensitivity, and ease of oper-
ation and handling during daily clinical usage. From an opti-
mistic perspective, the expected simplicity of use and the antic-
ipated comparatively low cost for a noninvasive diagnostic de-
vice allow anticipating an important role of such devices in pre-
ventive medicine, during widespread prescreening of patients,
and during monitoring of therapeutic progress, in particular, in
areas where more sophisticated or invasive diagnosis are not ei-
ther not available, or cannot be performed.
More likely than replacing existing techniques, breath anal-
ysis via MIR sensing systems may evolve into a complimen-
tary diagnostic method supporting currently existing diagnostic
techniques including, e.g., biopsy, blood sampling, mammog-
raphy, functional imaging, chromatographic separations, mass
spectrometry, etc. In particular, MIR sensing systems may de-
velop into an attractive option for less favored regions with lim-
ited access to sophisticated screening and analysis tool given
its potential for miniaturization and ultimate cost effectiveness
based on emerging integrated MIR photonics [132].
V. CONCLUSION
Though it has been a well-known fact that EB from patients
may provide information on a disease or the health status for
a long time, until recently EB has remained almost untouched
by modern (analytical) chemistry or medicine. EB (vapor and
condensate) contains more than 1000 chemical species ranging
in concentration from a few hundred of ppm down to ppt
levels. While VOCs in EB reflect the constituents also found
in blood, nonvolatile compounds contained in EB condensate
reflect biochemical changes related to the breathing airways
within their lining fluid. Therefore, significant compositional
and concentration changes of constituents within the EB (vapor
and condensate) matrix may potentially serve as an indicator
for diseases and/or the physiological status of an organism.
A variety of constituents have already been established as
identified biomarkers characteristic for certain diseases such
as, e.g., acetone, alkanes, NO, CO, , COS, , ,
leukotrienes, nitride/nitrate, isoprostanes, etc. Not only pul-
monary diseases, but also cancers, schizophrenia, diabetes,
Helicobacter pylori bacteria infection, and others may be
diagnosed by breath analysis. Among others, prevalent criteria
for clinically deployable breath analyzers include sensitivity to
ppt levels, sufficient molecular selectivity for discriminating
individual biomarkers, a compact footprint, (close to) real-time
monitoring, ease of operation, and cost efficiency. Evidently,
MIR spectroscopy ranks among the most promising analyt-
ical techniques complementing currently applied and mostly
laboratory-based analytical devices including, e.g., GC, MS,
chemiluminescence, etc., in a more compact, ideally handheld
format. In recent years, several MIR sensing techniques have
evolved into analytical tools with sensitivities ranging from
a few ppm to a few ppb yet with a rather compact device
footprint. QCL technology has been a vital addition to the
field of MIR sensing enabling compact breath analyzers with
small yet bright coherent light sources tailorable to almost
any wavelength across the entire MIR spectral band. Tun-
able EC-QCLs nowadays provide a tuning range of more
than 250 , thereby enabling the assessment of multiple
biomarkers in complex mixture. With the introduction of
semiconductor-based transducer/planar waveguide technology
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ideally complementing QCL light sources, a next important
building block for miniaturized sensing systems has recently
been established. In addition, hollow core waveguides simulta-
neously serving as MIR waveguide and as a highly efficient gas
cell are a promising approach for EB diagnostics, as a small
sample volume ( ) provides for an ideal transducer
in MIR sensing systems compared to usually much larger
conventional gas cells. PAS and QEPAS is another important
transducer technology, which enables developing compact
and sensitive sensing platforms in the MIR. For condensate
(liquid) analysis, Charlton et al. were the first to demonstrate
the utility of thin film planar waveguide technology coupled
with QCLs for detecting liquid phase and solid phase analytes,
which is an important first step toward MIR-based condensate
analysis. Finally, first clinical trials using TLAS and TDLAS
sensing systems demonstrate the emerging interest in bringing
MIR technology to bear in a clinical setting, and certainly
contribute to the acceptance of this measurement technique for
breath analysis. While a more widespread application of MIR
spectroscopy-based breath analyzers is desirable, a clinical
implementation requires meeting the emerging challenges of
improving the sensitivity of such devices along with a more
comprehensive understanding of the relevant biomarker panels
in EB and EBC.
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